Navigation Links
Antibody Drugs: Technologies and Global Markets
Date:3/21/2012

he "Technology and Technical Issues" section discusses new directions in antibody research, the types of antibodies used as therapeutics, the challenges in antibody production, and other approaches—in particular transgenic sources—of antibody production.

The "Products" section provides a synopsis of more than 60 mAb drugs, including those currently marketed and those in late-stage development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, sales by target and technology (for mAb-based drugs), as well as global market size and growth estimates for therapeutic mAbs.

The "Applications" section provides an overview of the leading indications for available and emerging antibody-based therapeutics. These include selected indications for autoimmune diseases (specifically rheumatoid arthritis, psoriasis, and Crohn's disease), cancer indications (specifically the most common solid tumor types, leukemias, and lymphomas) cardiovascular diseases, infectious diseases, ophthalmic indications, and respiratory diseases.

The "Industry Structure" section provides an overview of the antibody industry as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.

The "Company Profiles" section emphasizes companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

INFORMATION SOURCES

The information in this report was derived from the review of more than 200 biotechnology and pharmaceutical companies developing mAbs and the review of journal articles related to mAb therapeutics. Sources of information include PubMed, ClinicalTrials.gov, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMEA)
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
2. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
3. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
6. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
7. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
8. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  On August 5, 2015, the ... Oregon denied motions to dismiss securities class ... ) and certain of its directors. The class actions ... and dump" scheme to artificially inflate Galena,s stock price, ... stock price was inflated, sold massive amounts of their ...
(Date:8/31/2015)... , Aug. 31, 2015  Regulatory affairs ... government, where regulations are often strict and legislation ... driving a demand for professionals who have a ... regulations across a product lifecycle and demonstrate its ... University of California, Irvine Extension , in ...
(Date:8/31/2015)... SAN DIEGO , Aug. 31, 2015 ... announced today development of a novel means of ... nucleic acid, RGBP-248, to liver tumors utilizing a ... in development overcomes previous hurdles with gene silencing ... to be delivered throughout the whole body.  By ...
Breaking Medicine Technology:Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ... that Acetadote® ( acetylcysteine ) Injection, an injectable product ... available in the Australian market. Phebra Pty Ltd., an ... U.S.-based Cumberland Pharmaceuticals to market and distribute the product ...
... Biotechnology Corporation (Nasdaq: GNBT ) ( www.generex.com ) ... reverse stock split proposal put forward at the Annual Meeting ... DO NOT COUNT as votes cast in respect of ... Special Meeting of stockholders scheduled for 10 a.m. EDT on ...
Cached Medicine Technology:Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 5Generex Provides Clarification for Special Meeting Voting 2Generex Provides Clarification for Special Meeting Voting 3
(Date:8/31/2015)... , ... August 31, 2015 , ... Coast Dental ... September 5, 2015, from 11 a.m. to 3 p.m. near Albertsons in the Foothill ... opportunity to meet Dr. Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for ...
(Date:8/31/2015)... ... 2015 , ... Neuropsychiatric Disease and Treatment has ... near-infrared laser phototherapy ”. , As corresponding author Dr Theodore Henderson says “These ... with mostly palliative treatments only - and now we have shown real clinical ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... NJ Top Docs Presents, ... Doc”!, Born and raised in Park Ridge, New Jersey, Dr. Michael Betsy graduated from Don ... and ice hockey and served as team captain in both sports in his senior year. ...
(Date:8/31/2015)... ... August 31, 2015 , ... How ... and others—to hold down costs? , In a commentary for The American ... presents the concept of “clinical efficacy,” which would bind parties together in agreements ...
(Date:8/31/2015)... ... August 31, 2015 , ... The dental implant and prosthetic market ... Academy of Implant Dentistry. (See Press Room ) More than 30 million Americans ... procedure. With the increasing demand for dental implants, the National Association of Dental Laboratories ...
Breaking Medicine News(10 mins):Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4
... March 14 Sergeant,s Pet Care Products,today ... division of Virbac,Corporation. The brands and technology ... that include internal and external health care,products, ... Well recognized,brands include WormXPlus(TM), WormX(R), Petrodex(R), Zema(R), ...
... Ky. (Mar. 14, 2008) − Transcendental Meditation is ... with the added benefit of bypassing possible side ... a new meta-analysis conducted at the University of ... of the American Journal of Hypertension. , The ...
... the laboratory suggests that a new compound can point the ... latent form of the bacterium, says a team led by ... A drug with such properties could also be useful in ... treatment period. The discovery also points to new ways of ...
... at The University of Nottingham say modern matrons ... to fulfil their role as leader, and this remains ... healthcare. , Researchers at the Institute for Science and ... and unless significant budgetary responsibility is made part of ...
... ... Awareness Month, LOS ANGELES, March 14 Award-winning singer ... Valvo, who,is a colon cancer survivor, appear in a new ... The PSAs also note that,with advances in treatment, more people ...
... Serwik to Visit Washington, D.C., and Meet with Elected ... Del. will travel to Washington, D.C., this April 1 ... restoration of the,Americans with Disabilities Act, support for epilepsy ... epilepsy., Serwik, 7, is one of 50 young ...
Cached Medicine News:Health News:Sergeant's(R) Pet Care Products Acquires the Consumer Brand Division of Virbac Corporation 2Health News:New chemical can kill latent tuberculosis bacteria 2Health News:New chemical can kill latent tuberculosis bacteria 3Health News:Modern matron struggling to fulfil role as leader 2Health News:Vanessa Williams and Carmen Marc Valvo Make It Fashionable to Talk About Colon Cancer In New Public Service Announcement 2Health News:Vanessa Williams and Carmen Marc Valvo Make It Fashionable to Talk About Colon Cancer In New Public Service Announcement 3Health News:Delaware Youth Named National Epilepsy Spokesperson 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: